Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$72.66 ▼ -0.05
(-0.07%)
MKT CAP: $11.40B • VOL: 2.57M
52W L $43 52W H $73
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$61
MEDIAN
$81
MEAN
$83
HIGH
$99
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE TECH TAPE
TECH // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $87.92 | $83.56 | 2025-02-14 | $66.12 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $91.55 | $85.74 | 2025-02-06 | $68.30 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $82.83 | $79.93 | 2025-01-29 | $69.75 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $74.11 | — | 2025-01-17 | $71.21 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $63.94 | $69.03 | 2025-01-09 | $64.67 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $86.47 | $75.57 | 2024-12-18 | $63.21 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $70.48 | $73.39 | 2024-12-04 | $67.57 | -4.3% | 48% | C |